Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
A method of preventing or treating an immunological or inflammatory disease or disorder comprising administering a composition including a combination of rapamycin and metformin, wherein the molar ratio of rapamycin to metformin is in the range of about 20:1 to about 1:1; 10:1 to about 4:1; 5:1 to about 3:1; or about 5:1 to about 4:1. The composition may be formulated for oral administration, topical administration, parenteral administration, etc.
1. A method of treating an immunological or inflammatory disease or disorder comprising administering an effective amount of a composition comprising a combination of rapamycin and metformin to a subject, wherein the molar ratio of rapamycin to metformin is in the range of about 20:1 to about 1:1.
2. The method of claim 1 , wherein the molar ratio of rapamycin to metformin is in the range of about 15:1 to about 3:1.
3. The method of claim 1 , wherein the molar ratio of rapamycin to metformin is in the range of about 10:1 to about 4:1.
4. The method of claim 1 , wherein the molar ratio of rapamycin to metformin is about 5:1 to about 3:1.
5. The method of claim 1 , wherein the molar ratio of rapamycin to metformin is about 5:1 to about 4:1.
6. The method of claim 1 , wherein the inflammatory disease is an autoimmune and/or immunologically mediated inflammatory disease or disorder.
7. The method of claim 6 , wherein the autoimmune and/or immunologically mediated inflammatory disorder is selected from the group consisting of atopic dermatitis; inflammatory skin disease; inflammatory bowel disease; celiac disease; inflammatory airway disease; autoantibody-mediated autoimmune disease; discoid lupus; neurologic disease or disorder; systemic lupus (SLE); sarcoidosis; uveitis; pemphigus vulgaris; vasculitis; renal transplantation; and graft vs. host disease.
8. The method of claim 1 , wherein the method of treating comprises administering the composition to a patient at risk for developing or at risk for a recurrence of an immunological or inflammatory disease.
9. The method of claim 1 , wherein the composition is formulated for oral administration.
10. The method of claim 1 , wherein the composition is formulated for topical administration.
11. The method of claim 1 , wherein the composition is formulated for parenteral administration.
12. The method of claim 11 , wherein the composition comprises a nanoparticle encapsulating at least the rapamycin, the metformin, or the combination of rapamycin and metformin.
13. A method of treating an inflammatory disease or disorder mediated by mTORC1 activation comprising administering an effective amount of a composition comprising a combination of rapamycin and metformin to a subject, wherein the molar ratio of rapamycin to metformin is in the range of about 20:1 to about 1:1.
14. The method of claim 13 , wherein the molar ratio of rapamycin to metformin is in the range of about 10:1 to about 4:1.
15. The method of claim 13 , wherein the composition is formulated for parenteral administration.
16. The method of claim 15 , wherein the composition comprises a nanoparticle encapsulating at least the rapamycin, the metformin, or the combination of rapamycin and metformin.
17. The method of claim 13 , wherein the inflammatory disease or disorder is an autoimmune and/or immunologically mediated inflammatory disease or disorder.
18. A method of treating an immunological disease mediated by mTORC1 activation comprising administering an effective amount of a composition comprising a combination of rapamycin and metformin to a subject, wherein the molar ratio of rapamycin to metformin is in the range of about 20:1 to about 1:1.
19. The method of claim 18 , wherein the composition is formulated for parenteral administration.
20. The method of claim 19 , wherein the composition comprises a nanoparticle encapsulating at least the rapamycin, the metformin, or the combination of rapamycin and metformin.